Shire/Noven's Daytrana Receives FDA Wake-up Call: Side Effects Greater Than Concerta, Agency Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask FDA's Psychopharmacologic Drugs Advisory Committee whether the methylphenidate patch is "acceptably safe" for approval at Dec. 2 meeting.
You may also be interested in...
Shire/Noven Daytrana Second-Line? Physicians Should Consider Oral Agents First, Cmte. Says
FDA's Psychopharmacologic Drugs Advisory Committee suggests that broad initial use of the methylphenidate patch should be discouraged because of skin sensitization issues.
Shire/Noven Daytrana Second-Line? Physicians Should Consider Oral Agents First, Cmte. Says
FDA's Psychopharmacologic Drugs Advisory Committee suggests that broad initial use of the methylphenidate patch should be discouraged because of skin sensitization issues.
Shire/Noven Methypatch For ADHD To Be Reviewed By Psychopharm Committee
Companies seek indication for once-daily methylphenidate patch for the treatment of attention deficit/hyperactivity disorder in children ages six to 12 years.